Press Release
AB-Therapeutics to participate at the annual meeting of Association of Cancer Research (EACR) in Barcelona, Catalonia, Spain
During the congress the company will present new data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas, as well as data on toxicology and pharmacokinetics.
The work presented has been selected by the evaluation committee of the EACR.
The work presented has been selected by the evaluation committee of the EACR.
June 29, 2012
AB-Therapeutics, SL, pharmaceutical biotechnology company with a product in clinical phase planned for the first quarter of 2013, announced today that Jordi Espadaler, PhD, Senior Advisor, Discovery Research and co-founder, will participate in the Annual Meeting of the European Association of Cancer Research (AACR ) in Barcelona (July 7-10). Dr. Espadaler will present new data on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas with the compound ABTL0812, as well as data on toxicology and pharmacokinetics. The work presented has been selected by the evaluation committee of the EACR.
ABTL0812 presents significant advantages over conventional chemotherapy: very low toxicity, oral administration, and most importantly, high efficacy. The product affects two cellular processes related to cell division and thus the proliferation of cancer cells: a) synthesis of DNA through inhibition of the expression of the dihydrofolate reductase (DHFR) gene, and b) inhibiting mTOR pathway that is involved in protein synthesis. By blocking these two key cellular functions, tumor cells are killed by a mechanism called autophagy, in which cells digest themselves.
About AB Therapeutics, SL
AB Therapeutics, SL is a research and development biopharmaceutical company founded in 2009 with headquarters in Bellaterra (Barcelona), Catalonia, Spain, located at the campus of the Autonomous University of Barcelona and with facilities planned in Boston in the US for 2012.
AB Therapeutics, SL aims to develop safer human therapies, based on the modulation of the activity of cell-membranes to treat various cancers, especially those with high medical needs due to its high mortality. The firm has a molecule, ABTL0812, in regulatory preclinical development, Phase I clinical trials (First in Man) is planned for the third quarter of 2012. A second drug candidate, ABTL1014 will begin preclinical development during the last quarter of 2012.
Contact:
Press:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com
ABTL0812 presents significant advantages over conventional chemotherapy: very low toxicity, oral administration, and most importantly, high efficacy. The product affects two cellular processes related to cell division and thus the proliferation of cancer cells: a) synthesis of DNA through inhibition of the expression of the dihydrofolate reductase (DHFR) gene, and b) inhibiting mTOR pathway that is involved in protein synthesis. By blocking these two key cellular functions, tumor cells are killed by a mechanism called autophagy, in which cells digest themselves.
About AB Therapeutics, SL
AB Therapeutics, SL is a research and development biopharmaceutical company founded in 2009 with headquarters in Bellaterra (Barcelona), Catalonia, Spain, located at the campus of the Autonomous University of Barcelona and with facilities planned in Boston in the US for 2012.
AB Therapeutics, SL aims to develop safer human therapies, based on the modulation of the activity of cell-membranes to treat various cancers, especially those with high medical needs due to its high mortality. The firm has a molecule, ABTL0812, in regulatory preclinical development, Phase I clinical trials (First in Man) is planned for the third quarter of 2012. A second drug candidate, ABTL1014 will begin preclinical development during the last quarter of 2012.
Contact:
Press:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
www.ab-therapeutics.com
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com
LATEST NEWS
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
